IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.479
NA - Nord America 4.609
AS - Asia 4.492
SA - Sud America 773
AF - Africa 66
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 3
Totale 17.439
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.523
RU - Federazione Russa 3.314
SG - Singapore 1.684
IE - Irlanda 1.232
CN - Cina 998
IT - Italia 921
HK - Hong Kong 777
BR - Brasile 646
DE - Germania 435
GB - Regno Unito 411
UA - Ucraina 352
KR - Corea 312
FR - Francia 251
VN - Vietnam 211
FI - Finlandia 137
IN - India 133
SE - Svezia 124
JP - Giappone 111
GR - Grecia 108
TR - Turchia 85
CA - Canada 52
AR - Argentina 50
PK - Pakistan 41
NL - Olanda 40
AT - Austria 33
BE - Belgio 29
BD - Bangladesh 28
ID - Indonesia 26
EC - Ecuador 25
MX - Messico 24
ES - Italia 20
ZA - Sudafrica 20
CZ - Repubblica Ceca 17
CO - Colombia 15
PL - Polonia 15
MA - Marocco 14
IQ - Iraq 12
AZ - Azerbaigian 10
AU - Australia 9
CL - Cile 9
IL - Israele 9
IR - Iran 8
NZ - Nuova Zelanda 8
PE - Perù 8
CH - Svizzera 7
KE - Kenya 6
LT - Lituania 6
PY - Paraguay 6
VE - Venezuela 6
BJ - Benin 5
KG - Kirghizistan 5
UZ - Uzbekistan 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
EG - Egitto 4
HU - Ungheria 4
JO - Giordania 4
MK - Macedonia 4
RO - Romania 4
TN - Tunisia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
ET - Etiopia 3
KZ - Kazakistan 3
NP - Nepal 3
PH - Filippine 3
SA - Arabia Saudita 3
TH - Thailandia 3
BH - Bahrain 2
DZ - Algeria 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
LK - Sri Lanka 2
LV - Lettonia 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
GE - Georgia 1
IS - Islanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
Totale 17.437
Salva come PNG Salva come JPEG
Città #
Dublin 1.217
Moscow 1.076
Hong Kong 774
Singapore 729
Santa Clara 724
Chandler 669
Jacksonville 561
Seoul 292
Beijing 175
Naples 162
Princeton 162
Hefei 160
New York 160
Bremen 138
Dallas 137
Ashburn 136
Roxbury 129
Medford 121
Ann Arbor 120
Munich 103
The Dalles 93
Bengaluru 83
Caserta 79
Wilmington 72
Ho Chi Minh City 69
São Paulo 68
Los Angeles 63
Boardman 58
Cambridge 47
Nanjing 47
San Mateo 43
Des Moines 42
Woodbridge 38
Turku 37
Hanoi 36
Elora 34
Milan 34
Napoli 34
Nuremberg 32
Brussels 29
Dong Ket 22
Rio de Janeiro 22
Tianjin 22
Houston 21
Amsterdam 18
Brooklyn 17
Falkenstein 17
Mountain View 17
Shanghai 17
Vienna 17
Brno 16
Brasília 15
Nanchang 15
Norwalk 15
Rome 15
Aversa 14
Columbus 14
Jakarta 13
Lappeenranta 13
Rawalpindi 13
Tokyo 13
Warsaw 13
Belo Horizonte 12
Helsinki 12
Jinan 12
London 12
San Francisco 12
Changsha 11
Council Bluffs 11
Ercolano 11
Hangzhou 11
Istanbul 11
Baku 10
Guangzhou 10
Haiphong 10
Atlanta 9
Chicago 9
Curitiba 9
Düsseldorf 9
Hải Dương 9
Zhengzhou 9
Bahawalpur 8
Bogotá 8
Boston 8
Campinas 8
Cape Town 8
Castello di Brianza 8
Changchun 8
Guayaquil 8
Johannesburg 8
Kunming 8
Madrid 8
Manchester 8
Redwood City 8
Seattle 8
Cava Dei Tirreni 7
Mauá 7
Phoenix 7
Pozzuoli 7
Shenyang 7
Totale 9.488
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 178
ONCOLOGIA MEDICA 174
Beyond N staging in colorectal cancer: Current approaches and future perspectives 152
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 152
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 140
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 137
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 136
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 136
AXL is an oncotarget in human colorectal cancer 132
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 131
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 128
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 125
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 123
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 121
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 121
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 119
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 118
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 117
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 116
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 115
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 115
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 114
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 114
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 113
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 113
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 112
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 111
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 108
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 107
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 107
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 107
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 106
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 106
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 105
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 105
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 104
Farmacogenomica e cancro colorettale 104
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 104
TRASTUZUMAB RESISTANCE IN BREAST CANCER 103
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 103
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 102
Antiangiogenic drugs in non small cell lung cancer treatment 101
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 101
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 100
Small Bowel Metastasis in a Stage IV Melanoma Patient: A Report of Multimodal Approach 100
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 99
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 99
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 99
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 98
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 98
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 97
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 97
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 97
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 97
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 97
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 97
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 97
To Get the Most out of the Least: BRAF Molecular Evaluation in Melanoma Metastases on Cell Suspension from Fine Needle Aspiration Cytology Needle Rinses 96
Targeting EGFR in Pancreatic Cancer Treatment. 96
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 95
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 95
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 95
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 95
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 95
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 94
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 92
Therapeutic integration of signal trasdution targeting agents an conventional anticancer treatments 92
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 92
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 90
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 90
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 90
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 89
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model 89
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 89
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 88
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 88
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 87
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 87
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 86
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 86
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 85
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 85
Metformin in lung cancer: rationale for a combination therapy 85
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 85
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 85
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. 85
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 85
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 85
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 85
Vandetaninb, a dual inhibitor of VEGFR and EGFR tyrosine kinase activity 84
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 84
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 84
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 84
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 83
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 83
It is finally time for adjuvant therapy in melanoma 83
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 83
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC 82
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 82
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients 82
Totale 10.283
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.751
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021563 0 0 0 0 0 25 119 96 29 115 124 55
2021/20221.163 57 26 27 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/20253.522 61 93 47 139 527 462 453 328 466 379 308 259
2025/20266.785 609 716 748 734 1.213 2.765 0 0 0 0 0 0
Totale 17.933